MedPath
Found 1 clinical trials|View Analysis
Sort by:

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Phase 1
Completed
Conditions
Solid Tumor
Advanced Solid Tumor
Interventions
Drug: M4344 40 mg BIW
Drug: M4344 100 mg BID
Drug: M4344 150 mg QD
Drug: M4344 350 mg QD
Drug: M4344 10 mg BIW
Drug: M4344 20 mg BIW
Drug: M4344 160 mg BIW
Drug: M4344 1200 mg BIW
Drug: M4344 700 mg BIW
Drug: M4344 80 mg BIW
Drug: M4344 1050 mg BIW
Drug: M4344 300 mg BIW
Drug: M4344 450 mg BIW
Drug: M4344 250 mg QD
Drug: M4344 400 mg
Drug: M4344 500 mg
Drug: Carboplatin
First Posted Date
2014-10-29
Last Posted Date
2023-03-16
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Target Recruit Count
97
Registration Number
NCT02278250
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 13 locations
© Copyright 2025. All Rights Reserved by MedPath